12
1
7
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T83706 |
BMAP 28 (bovine) TFA
Cathelicidin-5 (132-158),Bovine Myeloid Antimicrobial Peptide 28 |
||
BMAP 28是一种合成抗菌肽,对应牛防御素-5的132-158氨基酸。对大肠杆菌(E. coli)、金黄色葡萄球菌(S. aureus)、耐甲氧西林金黄色葡萄球菌(MRSA)、表皮葡萄球菌(S. epidermidis)及白色念珠菌(C. albicans)具有活性(MICs分别为2、2、4、1和8 µM)。在200 nM浓度下,BMAP 28能够使大肠杆菌的内膜渗透。在5 µM浓度下,减少Vero 76细胞中单纯疱疹病毒1型(HSV-1)的复制。在30 µM浓度下,对分离的人类红细胞引起溶血,并对分离的人类嗜中性粒细胞具有细胞毒性。BMAP 28 (0.8 mg/kg)可提高大肠杆菌或MRSA感染的小鼠的生存率,但对铜绿假单胞菌(P. aeruginosa)感染的小鼠无效。 | |||
TP1775L |
LL-37, Human acetate(154947-66-7 free base)
|
Antibacterial | Microbiology/Virology |
LL-37, Human acetate(154947-66-7 free base) 是一种 37 个残基、两亲性、cathelicidin 衍生的抗菌肽,具有广谱的抗菌活性。 | |||
TP1775 |
LL-37, Human
|
||
LL-37, Human is a 37-residue, amphipathic, cathelicidin-derived antimicrobial peptide, which exhibits a broad spectrum of antimicrobial activity. | |||
T80261 |
Retro-indolicidin
|
||
Retro-indolicidin为一具有生物活性的肽,由13个氨基酸残基组成,依据indolicidin序列设计而成。Indolicidin属于cathelicidin蛋白家族,为从牛中性粒细胞细胞质颗粒分离得到的阳离子抗菌肽酰胺。该合成肽(Rev4)已证实显示出显著的体外抗菌和蛋白酶抑制活性。 | |||
T75857 |
LL-37, human TFA
|
||
LL-37, human TFA 是一种由37个氨基酸残基组成的两亲性抗菌肽,源自组织蛋白酶,具备广谱抗菌活性。该化合物有助于防护角膜避免感染,同时调节伤口的愈合过程。 | |||
T80252 |
BMAP-18
|
||
BMAP-18为一抗菌肽,是Cathelicidin肽家族中的成员,为BMAP-27的截短版,具备针对Staphylococcus aureus、Streptococcus uberis和Escherichia coli的快速杀菌作用。相比其亲本BMAP-27,BMAP-18展现出优越的细胞选择性,降低了对人红细胞和中性粒细胞的溶血作用,同时保留其抗菌能力。 | |||
T80245 |
LL-37(17-32)
|
||
LL-37(17-32)为具有生物活性的肽段,为LL-37抗菌肽C末端结构域源自的活性片段。报道显示,LL-37(17-32)能逆转癌细胞系中ABCG2介导的多药耐药性。 | |||
T80263 |
Tet-20
|
||
Tet-20是一种合成导管素衍生的生物活性肽。此化合物作为医疗器械抗感染涂层的测试表明,它固定于植入物表面后,在体内和体外均展现了广泛的抗菌活性,能有效抑制生物膜的形成,且对真核细胞无毒。 | |||
T75858 |
LL-37, human acetate
|
||
LL-37, human acetate 是一种由37个氨基酸残基组成的两亲性抗菌肽,源于组织蛋白酶的衍生物,展现出广泛的抗菌效果。该化合物不仅对角膜感染提供保护,也有助于调节伤口的愈合过程。 | |||
T83738 |
SMAP 29 (ovine) TFA
Sheep Myeloid Antimicrobial Peptide 29 |
||
SMAP 29是一种抗微生物肽,同时也是绵羊防御素前体肽的C末端切割产物。在低盐和高盐条件下,对P. aeruginosa菌株PAO1具有杀菌作用,该作用在能量依赖的发光测定中表现出来(EC50s分别为0.05和0.06 µM)。它还能够以浓度依赖的方式引起绵羊红细胞的溶血。 | |||
T83698 |
Cathelicidin-2 (128-153) (chicken) TFA
Fowlicidin-2 (128-153),CATH-2 (128-153),Myeloid Antimicrobial Peptide 27 (128-153) |
||
Cathelicidin-2 (CATH-2) (128-153) 是一种合成抗菌肽,对应于鸡CATH-2的128至153个氨基酸。该化合物对E. coli、S. aureus、S. enteritidis和B. globigii展示出浓度依赖性的活性。CATH-2 (128-153) (40 µM) 可诱导孤立的鸡红细胞溶解,但对孤立的人外周血单个核细胞(PBMCs)无细胞毒性。它能促进化学因子(C-C-基序)配体2 (CCL2)的产生,并抑制LPS诱导的TNF-α、IL-6、IL-8和IL-10在孤立的人PBMCs中的产生。 | |||
T35451 |
β-Defensin-2 (human) (trifluoroacetate salt)
|
||
β-Defensin-2 is a peptide with antimicrobial properties that protects the skin and mucosal membranes of the respiratory, genitourinary, and gastrointestinal tracts.1It inhibits the growth of periodontopathogenic and cariogenic bacteria, includingP. gingivalisandS. salivarius.2β-Defensin-2 (30 μg/ml) stimulates gene expression and production of IL-6, IL-10, CXCL10, CCL2, MIP-3α, and RANTES by keratinocytes.3It also stimulates calcium mobilization, migration, and proliferation of keratinocytes whe... |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
TQ0216 |
Ercalcitriol
1α,25-Dihydroxy Vitamin D2 |
Others | Others |
Ercalcitriol (1α,25-Dihydroxy Vitamin D2) 是维生素 D2 的活性代谢物。 Ercalcitriol 作为维生素 D 的生理活化形式,通过调节正常细胞和转化细胞中的导管素抗菌肽 (CAMP) 和防御素 β-4 (DEFB4) 基因来增强免疫力,从而对抗病原体感染。 |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPH-01058 |
Cathelicidin antimicrobial peptide Protein, Human, Recombinant (His & Myc & SUMO)
CAP18,Cathelicidin antimicrobial pepti... |
Human | E. coli |
Binds to bacterial lipopolysaccharides (LPS), has antibacterial activity. Cathelicidin antimicrobial peptide Protein, Human, Recombinant (His & Myc & SUMO) is expressed in E. coli expression system with N-10xHis-SUMO and C-Myc tag. The predicted molecular weight is 24.7 kDa and the accession number is P49913. | |||
TMPK-01491 |
HLA-A*02:01&B2M&HBV (FLLTRILTI) Monomer Protein, Human, MHC (His & Avi), Biotinylated
MHC,HBV,Hepatitis B virus |
Human | HEK293 Cells |
Hepatitis B virus (HBV), is the leading cause of liver diseases infecting an estimated 240 million persons worldwide. The HBV prevalence rates are variables between different countries, with an high level of endemicity in the south-eastern part of Europe. Seven main HBV-D subgenotypes have been described until now (D1-D7). | |||
TMPK-01501 |
HLA-A*02:01&B2M&HBV (FLLTRILTI) Tetramer Protein, Human, MHC (His & Avi)
MHC,Hepatitis B virus,HBV |
Human | HEK293 Cells |
Hepatitis B virus (HBV), is the leading cause of liver diseases infecting an estimated 240 million persons worldwide. The HBV prevalence rates are variables between different countries, with an high level of endemicity in the south-eastern part of Europe. Seven main HBV-D subgenotypes have been described until now (D1-D7). | |||
TMPK-01505 |
HLA-A*02:01&B2M&HPV16 E7 (YMLDLQPET) Monomer Protein, Human, MHC (His & Avi), Biotinylated
E7,MHC,HPV16 |
Human | HEK293 Cells |
HPV16 E7 protein, one of the primary target proteins in molecular targeted therapy for HPV-induced cervical cancer. The affitoxin, ZHPV16E7 affitoxin384 was generated by fusing the modified Pseudomonas Exotoxin A (PE38KDEL) to the HPV16 E7-specific affibody. | |||
TMPK-01492 |
HLA-A*02:01&B2M&HBV (FLLTRILTI) Monomer Protein, Human, MHC (His & Avi)
Hepatitis B virus,HBV,MHC |
Human | HEK293 Cells |
Hepatitis B virus (HBV), is the leading cause of liver diseases infecting an estimated 240 million persons worldwide. The HBV prevalence rates are variables between different countries, with an high level of endemicity in the south-eastern part of Europe. Seven main HBV-D subgenotypes have been described until now (D1-D7). | |||
TMPK-01504 |
HLA-A*02:01&B2M&HPV16 E7 (YMLDLQPET) Tetramer Protein, Human, MHC (His & Avi)
MHC,HPV16,E7 |
Human | HEK293 Cells |
HPV16 E7 protein, one of the primary target proteins in molecular targeted therapy for HPV-induced cervical cancer. The affitoxin, ZHPV16E7 affitoxin384 was generated by fusing the modified Pseudomonas Exotoxin A (PE38KDEL) to the HPV16 E7-specific affibody. | |||
TMPK-01506 |
HLA-A*02:01&B2M&HPV16 E7 (YMLDLQPET) Monomer Protein, Human, MHC (His & Avi)
HPV16,E7,MHC |
Human | HEK293 Cells |
HPV16 E7 protein, one of the primary target proteins in molecular targeted therapy for HPV-induced cervical cancer. The affitoxin, ZHPV16E7 affitoxin384 was generated by fusing the modified Pseudomonas Exotoxin A (PE38KDEL) to the HPV16 E7-specific affibody. |